نتایج جستجو برای: disease activity score 28

تعداد نتایج: 2762078  

Journal: :The Egyptian journal of immunology 2013
Esam M Abu Al Fadl Mona Fattouh Ahmed A Allam

Rheumatoid arthritis (RA) is a chronic autoimmune systemic disorder characterized by inflammatory responses mainly affecting the synovial joints. Interleukin-23 (IL-23) is a heterodimeric pro-inflammatory cytokine secreted by activated dendritic cells and activated macrophages. IL-23 is the key cytokine controlling inflammation in peripheral tissues leading to the development of autoimmune dise...

Journal: :Egyptian Rheumatology and Rehabilitation 2022

Abstract Background Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation and joint destruction that eventually induces severe disability. Inflammation the key determinant primary underlying mechanism leading to disability increased mortality in patients with RA. This study aimed correlate hematological markers ultrasound 7-joint score activity rheumatoid pat...

Journal: :Arthritis Research & Therapy 2007
João Eurico Fonseca João Cavaleiro José Teles Elsa Sousa Valeska L Andreozzi Marília Antunes Maria A Amaral-Turkman Helena Canhão Ana F Mourão Joana Lopes Joana Caetano-Lopes Pamela Weinmann Marta Sobral Patrícia Nero Maria J Saavedra Armando Malcata Margarida Cruz Rui Melo Araceli Braña Luis Miranda José V Patto Anabela Barcelos José Canas da Silva Luís M Santos Guilherme Figueiredo Mário Rodrigues Herberto Jesus Alberto Quintal Teresa Carvalho José A Pereira da Silva Jaime Branco Mário Viana Queiroz

The objective of this study was to assess whether clinical measures of rheumatoid arthritis activity and severity were influenced by tumor necrosis factor-alpha (TNF-alpha) promoter genotype/haplotype markers. Each patient's disease activity was assessed by the disease activity score using 28 joint counts (DAS28) and functional capacity by the Health Assessment Questionnaire (HAQ) score. System...

2013
Frank Buttgereit Daksha Mehta John Kirwan Jacek Szechinski Maarten Boers Rieke E Alten Jerzy Supronik Istvan Szombati Ulrike Romer Stephan Witte Kenneth G Saag

OBJECTIVE To assess the efficacy and safety of low-dose prednisone chronotherapy using a new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA). METHODS In this 12-week, double-blind, placebo-controlled study, patients with active RA (n=350) were randomised 2:1 to receive MR prednisone 5 mg or placebo once daily in the evening in addition to their existing RA dis...

2014
Stinne Ravn Greisen Karen Kræmmer Schelde Tue Kruse Rasmussen Tue Wenzel Kragstrup Kristian Stengaard-Pedersen Merete Lund Hetland Kim Hørslev-Petersen Peter Junker Mikkel Østergaard Bent Deleuran Malene Hvid

INTRODUCTION A key phenomenon in rheumatoid arthritis is the formation of lymphoid follicles in the inflamed synovial membrane. C-X-C motif chemokine 13 (CXCL13) is central in this process as it attracts C-X-C chemokine receptor type 5 (CXCR5)-expressing B cells and T follicular helper cells to the follicle. We here examine the role of CXCL13 and its association with disease in patients with tr...

Journal: :Arthritis Research & Therapy 2008
Jennie Ursum Markus MJ Nielen Dirkjan van Schaardenburg Ann R van der Horst Rob J van de Stadt Ben AC Dijkmans Dörte Hamann

INTRODUCTION The aim of our study was to investigate the association between arthritic disease activity and antibodies to mutated citrullinated vimentin (anti-MCV), because such a relation has been suggested. METHODS Anti-MCV levels were measured in 162 patients with early arthritis (123 with rheumatoid arthritis and 39 with undifferentiated arthritis) at baseline and at 1 and 2 years of foll...

2016
Gurjit S. Kaeley Midori J. Nishio Janak R. Goyal Daryl K. MacCarter Alvin F. Wells Su Chen Hartmut Kupper Jasmina Kalabic

OBJECTIVE To assess joint disease activity by ultrasound (US) in patients with rheumatoid arthritis (RA) initiating treatment with adalimumab (ADA) plus methotrexate (MTX). METHODS Data for this post hoc analysis originated from the MUSICA trial (ClinicalTrials.gov identifier: NCT01185288), which evaluated the efficacy of initiating ADA (40 mg every other week) plus 7.5 or 20 mg/week MTX in 3...

2012
R. Sakthiswary S. Syahrul Sazliyana M.S. Mohd Shahrir N.S. Shahril H. Hussein

Tumor necrosis factor alpha (TNFα) is a multifunctional cytokine which plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA). Apart from its well recognized proinflammatory properties, it is known to interfere with lipid metabolism and erythropoiesis. We evaluated the effects of adalimumab on hematologic, lipid and inflammatory parameters using data from patients on adalimumab 4...

Journal: :Annals of the rheumatic diseases 1999
J Teir J Gray A Pendlebury D M Grennan

We have been interested in the publication by Möttönen and colleagues concerning the outcome of patients with early rheumatoid arthritis (RA) who have been treated actively by disease suppressing drugs using a “sawtooth” strategy 2 and have assessed the outcomes in our patients with early RA who have been treated using a similar strategy. Our study is prospective for five years and started in 1...

Journal: :Therapeutic drug monitoring 2010
Denis Mulleman Delphine Chu Miow Lin Emilie Ducourau Patrick Emond David Ternant Charlotte Magdelaine-Beuzelin Jean-Pierre Valat Gilles Paintaud Philippe Goupille

Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha and is approved for refractory rheumatoid arthritis. We studied the association between infliximab concentration and long-term control of disease activity in patients with rheumatoid arthritis treated on a routine basis both in cross-sectional analysis and over the long term. Trough serum infliximab con...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید